Type 2 CRSwNP is linked to worse health-related quality of life, with higher rates of smell loss and rhinorrhea emerging as ...

French pharma major Sanofi and US partner Regeneron Pharmaceuticals yesterday presented positive results from the EVEREST ...

In patients with chronic rhinosinusitis with nasal polyps, factors including baseline antibiotic use and asthma impacted the ...

Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress describe ...

A new Canadian real-world study, ACTIONS (chAracterizing oral Corticosteroid use in patients with chronic rhInOsinusitis with ...

The prevalences of allergic rhinitis and asthma were more common in the CRSwNP group compared with the CRSsNP group (P < .05 for both), at 43.6% vs 19.8% and 48.2% vs 15.1%, respectively, but ...

Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) - Market Insights, Epidemiology, and Market Forecast - 2032" report has been added to ...

This new study explored how expression of SERPINB10 may be related to postoperative recurrence of and inflammation related to chronic rhinosinusitis with nasal polyps (CRSwNP). SERPINB10 ...

This approval expands the initial June 2019 FDA approval in CRSwNP for patients aged 18 years and older. The FDA evaluated Dupixent for this expanded indication under Priority Review, which is ...

The approval in adolescent patients with CRSwNP was also supported by pharmacokinetic data from adult and pediatric patients aged 12 years and older with moderate to severe asthma and adult ...

The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with ...

UK-based pharmaceutical company GSK has reported positive outcomes from two Phase III trials of depemokimab for treating ...